CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

ilorasertib

Small moleculeexperimental

Clinical trial activity

4 trials · 4 clinical orgs · 0 marketing orgs

Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0

Earliest trial started Mar 1, 2010 (NCT01110486)

Timeline

2010s

  1. Jan 1, 2010

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2016

    Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
Mol. weight
488.55 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 1-(4-(4-amino-7-(1-(2-hydroxyethyl)-1h-pyrazol-4-yl)thieno(3,2-c)pyridin-3-yl)phenyl)-3-(3-fluorophenyl)urea
  • a-968660
  • a-968660
  • abt-348
  • abt-348
  • abt-348
  • abt-348
  • ilorasertib
  • ilorasertib
  • ilorasertib
  • ilorasertib
  • ilorasertib

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02478320Phase 2Aug 1, 2016AbbVie, University of Texas at Houston
NCT02540876Phase 1Sep 1, 2015National Cancer Institute (NCI), University of Chicago
NCT01110473Phase 1Apr 1, 2010AbbVie
NCT01110486Phase 1Mar 1, 2010AbbVie
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (4)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
AbbVieFor profit3222010
National Cancer Institute (NCI)Government1012015
University of ChicagoAcademic/Hospital1112015
University of Texas at HoustonAcademic/Hospital1112016
4 organizations
Page 1 / 1